Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Brain Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • Gene Rearrangement
  • Lung Neoplasms
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyridines
  • Receptor Protein-Tyrosine Kinases

abstract

  • Crizotinib was associated with systemic and intracranial disease control in patients with ALK-rearranged NSCLC who were ALK inhibitor naive and had brain metastases. However, progression of preexisting or development of new intracranial lesions while receiving therapy was a common manifestation of acquired resistance to crizotinib.

publication date

  • June 10, 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4451171

Digital Object Identifier (DOI)

  • 10.1200/JCO.2014.59.0539

PubMed ID

  • 25624436

Additional Document Info

start page

  • 1881

end page

  • 8

volume

  • 33

number

  • 17